Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected ...

Ever wonder how celebrities always seem red carpet ready? Melanie Speed of Flawless Med Spa shares some insight.

New therapeutic 'cocktails' may provide long-lasting relief for treatment-resistant asthma and other immune system inflammatory diseases.

Two therapeutic "cocktails" could stop immune cells from overreacting to allergens, providing long-lasting asthma relief.

Current asthma treatments don't work in all patients, and they don't provide long-term relief from potentially deadly asthma ...